Skip to content
Screener

Avalo Therapeutics AVTX Other operating expenses

Discontinued — last reported Q3 '19

Other operating expenses at other companies

Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$16.16M+24.0%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$60.19M+8.8%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$66.83M+0.2%
Alumis Inc. logo
Alumis Inc.ALMS
$100.15M-15.8%
Vera Therapeutics logo
Vera TherapeuticsVERA
$125.13M+119%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$36.43M+45.2%

Segments

By segment

See full
Reportable Segment$79K-32.5%

Other financials

Income statement

See full
Revenue$59.0K-69.3%
Gross profit$963.0K+8,855%
Operating income-$31.5M-63.2%
Net income-$36.4M-75.1%
EPS (diluted)-$0.83+56.8%

Balance sheet

See full
Cash & equivalents$85.6M+101%
Total debt$242.0K-64.4%
Total equity$448.7M+329%
Total assets$490.8M+288%

Cash flow

See full
Operating cash flow-$20.0M-75.5%
CapEx-—
Free cash flow-$15.0M-444%

Valuation

See full
Market cap$982.5M+908%
Enterprise value$897.13M+1,512%

Profitability

See full
Gross margin182%+176pp
Operating margin-15,536.1%-17,275pp
Net margin-7,965.8%-10,750pp
FCF margin-11,123.8%-13,374pp

Returns & leverage

See full
Return on equity-36.3%—
Debt / equity0×0.0×
Current ratio19.3×+6.9×

Where this comes from

Reported directly by Avalo Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The source filing: Avalo Therapeutics’s 10-Q, filed November 14, 2019. Open the filing →

Filed
Nov 14, 2019
Fiscal quarter
Q3 FY2019
Calendar quarter
Q3 2019
Accession
0001628280-19-014207

FAQ

What does other operating expenses mean?
Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.